Do mornings make cancer immunotherapy more effective? Study: Maybe

A curious phenomenon seen by oncologists, that morning patients do better than those receiving afternoon infusions, gains credence in a clinical trial.

By Angus Chen

STAT+ | Why Bristol Myers Squibb believes a decades-old drug can treat Alzheimer’s

BMS faces a $20 billion annual revenue loss as its biggest drugs lose patent protection. It's counting heavily on an old drug's new use against Alzheimer's.

By Damian Garde

Fearing ICE crackdown, immigrants nationally are avoiding treatment, sometimes with dire consequences

Patients, fearing arrest, wait longer for care or skip it. Doctors and health system leaders say the disruption poses a risk to public health.

By Daniel Payne

Vinay Prasad is head of the FDA’s Center for Biologics Evaluation and Research.

Courtesy FDA

STAT+ | FDA officials push for long-term monitoring of autoimmune patients receiving CAR-T therapy

Three FDA officials suggest long-term follow-up studies of CAR-T therapies for autoimmune disorders, citing possible concerns with cancer, infertility.

By Allison DeAngelis

More around STAT

Thibaut Durand / Hans Lucas / AFP via Getty Images